Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis

Survey on Anemia Therapy With ESAs Medication in Chronic Kidney Disease Patients Not on Dialysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02238067

Enrollment

196

Registered

2014-09-12

Start date

2011-09-30

Completion date

2013-08-31

Last updated

2017-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Brief summary

This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis participant population in Israel. Participating physicians will be requested to interview eligible participants with CKD not on dialysis and to complete for them a satisfaction survey for anemia treatment. The survey will be completed twice, once at study start and once at six months' follow-up.

Interventions

DRUGESA

Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.

OTHERSatisfaction Survey Questionnaire

Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult participants with CKD Stage 3-5 * Treated with ESAs * Participant is speaking the same language as the investigator interviewer

Exclusion criteria

* Past or current treatment with dialysis

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants by ESA Types at Month 6	Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Percentage of Participants by ESA Types at Baseline	Baseline	Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Percentage of Participants by Frequency of ESA Use at Baseline	Baseline	Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Percentage of Participants by Frequency of ESA Use at Month 6	Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Percentage of Participants by Frequency and Types of ESA Used at Baseline	Baseline	Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Percentage of Participants by Frequency and Types of ESA Used at Month 6	Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.

Secondary

Measure	Time frame	Description
Percentage of Participants by Preferred Treatment Frequency by ESA Type	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.
Percentage of Participants by Different CKD Stages	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.
Percentage of Participants by Convenience of Syringe Usage by ESA Type	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.
Percentage of Participants by Injection Site Pain	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.
Percentage of Participants by Injection Site Pain by ESA Type	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.
Percentage of Participants by Convenience of Syringe Usage	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.
Percentage of Participants by Different Injection Administration Modes	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.
Percentage of Participants With Interest in Learning to Inject Independently	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.
Percentage of Participants by Need for Improvement in Treatment Frequency	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.
Percentage of Participants by Preferred Treatment Frequency	Baseline, Month 6	Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.

Countries

Israel

Participant flow

Participants by arm

Arm	Count
Chronic Renal Anemia Participants Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.	196
Total	196

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Not completed survey at Month 6	45

Baseline characteristics

Characteristic	Chronic Renal Anemia Participants
Age, Continuous	74.6 years STANDARD_DEVIATION 10.6
Sex: Female, Male Female	85 Participants
Sex: Female, Male Male	111 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 0
serious Total, serious adverse events	3 / 196

Outcome results

Primary

Percentage of Participants by ESA Types at Baseline

Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.

Time frame: Baseline

Population: All enrolled participants

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Baseline	Mircera	51.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Baseline	Recormon	17.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Baseline	Eprex	10.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Baseline	Aranesp	20.4 percentage of participants

Primary

Percentage of Participants by ESA Types at Month 6

Time frame: Month 6

Population: All enrolled participants who completed the questionnaire at Month 6

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Month 6	Aranesp	24.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Month 6	Mircera	43.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Month 6	Recormon	19.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by ESA Types at Month 6	Eprex	12.6 percentage of participants

Primary

Percentage of Participants by Frequency and Types of ESA Used at Baseline

Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.

Time frame: Baseline

Population: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Three times a week (n=100)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Twice a week (n=100)	4.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Once a week (n=100)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Every 2 weeks (n=100)	26.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Every 4 weeks (n=100)	67.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Mircera : Other (n=100)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Three times a week (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Twice a week (n=34)	17.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Once a week (n=34)	38.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Every 2 weeks (n=34)	17.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Every 4 weeks (n=34)	5.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Recormon : Other (n=34)	20.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Three times a week (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Twice a week (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Once a week (n=21)	42.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Every 2 weeks (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Every 4 weeks (n=21)	4.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Eprex : Other (n=21)	23.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Three times a week (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Twice a week (n=40)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Once a week (n=40)	15.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Every 2 weeks (n=40)	42.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Every 4 weeks (n=40)	12.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Baseline	Aranesp : Other (n=40)	22.5 percentage of participants

Primary

Percentage of Participants by Frequency and Types of ESA Used at Month 6

Time frame: Month 6

Population: All enrolled participants who completed the questionnaire at Month 6. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Three times a week (n=66)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Twice a week (n=66)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Once a week (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Every 2 weeks (n=66)	18.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Every 4 weeks (n=66)	71.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Mircera : Other (n=66)	7.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Three times a week (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Twice a week (n=29)	10.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Once a week (n=29)	27.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Every 2 weeks (n=29)	37.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Every 4 weeks (n=29)	6.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Recormon : Other (n=29)	17.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Three times a week (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Twice a week (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Once a week (n=19)	47.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Every 2 weeks (n=19)	15.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Every 4 weeks (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Eprex : Other (n=19)	21.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Three times a week (n=37)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Twice a week (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Once a week (n=37)	18.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Every 2 weeks (n=37)	32.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Every 4 weeks (n=37)	24.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency and Types of ESA Used at Month 6	Aranesp : Other (n=37)	21.6 percentage of participants

Primary

Percentage of Participants by Frequency of ESA Use at Baseline

Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.

Time frame: Baseline

Population: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Three times a week	2.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Twice a week	7.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Once a week	14.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Every 2 weeks	26.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Every 4 weeks	38.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Baseline	Other	10.8 percentage of participants

Primary

Percentage of Participants by Frequency of ESA Use at Month 6

Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.

Time frame: Month 6

Population: All enrolled participants who completed the questionnaire at Month 6

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Three times a week	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Twice a week	4.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Once a week	15.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Every 2 weeks	25.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Every 4 weeks	39.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Frequency of ESA Use at Month 6	Other	14.6 percentage of participants

Secondary

Percentage of Participants by Convenience of Syringe Usage

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 1: Baseline (n=196)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 3: Baseline (n=196)	2.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 4: Baseline (n=196)	6.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 5: Baseline (n=196)	88.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 1: Month 6 (n=151)	0.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 3: Month 6 (n=151)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 4: Month 6 (n=151)	4.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage	Score 5: Month 6 (n=151)	93.4 percentage of participants

Secondary

Percentage of Participants by Convenience of Syringe Usage by ESA Type

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 1: Baseline (n=101)	4.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 3: Baseline (n=101)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 4: Baseline (n=101)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 5: Baseline (n=101)	90.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 1: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 3: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 4: Month 6 (n=66)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Mircera: Score 5: Month 6 (n=66)	98.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 1: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 3: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 4: Baseline (n=34)	11.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 5: Baseline (n=34)	85.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 1: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 3: Month 6 (n=29)	3.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 4: Month 6 (n=29)	6.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Recormon: Score 5: Month 6 (n=29)	89.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 1: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 3: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 4: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 5: Baseline (n=21)	100.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 1: Month 6 (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 3: Month 6 (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 4: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Eprex: Score 5: Month 6 (n=19)	89.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 1: Baseline (n=40)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 3: Baseline (n=40)	7.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 4: Baseline (n=40)	10.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 5: Baseline (n=40)	82.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 1: Month 6 (n=37)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 3: Month 6 (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 4: Month 6 (n=37)	8.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Convenience of Syringe Usage by ESA Type	Aranesp: Score 5: Month 6 (n=37)	89.2 percentage of participants

Secondary

Percentage of Participants by Different CKD Stages

Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 1 : Baseline (n=196)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 1 : Month 6 (n=151)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 2 : Baseline (n=196)	10.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 2 : Month 6 (n=151)	13.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 3 : Baseline (n=196)	37.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 3 : Month 6 (n=151)	41.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 4 : Baseline (n=196)	37.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 4 : Month 6 (n=151)	30.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 5 : Baseline (n=196)	12.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different CKD Stages	Stage 5 : Month 6 (n=151)	12.6 percentage of participants

Secondary

Percentage of Participants by Different Injection Administration Modes

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Independently : Baseline (n=196)	18.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Independently : Month 6 (n=151)	23.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	By a family member : Baseline (n=196)	16.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	By a family member : Month 6 (n=151)	17.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Nurse at home : Baseline (n=196)	3.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Nurse at home : Month 6 (n=151)	3.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Nurse at the clinic : Baseline (n=196)	58.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Nurse at the clinic : Month 6 (n=151)	52.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Other: Baseline (n=196)	3.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Different Injection Administration Modes	Other : Month 6 (n=151)	3.3 percentage of participants

Secondary

Percentage of Participants by Injection Site Pain

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 1: Baseline (n=196)	88.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 1: Month 6 (n=151)	92.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 2: Baseline (n=196)	8.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 2: Month 6 (n=151)	6.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 3: Baseline (n=196)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 3: Month 6 (n=151)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 4: Baseline (n=196)	0.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 4: Month 6 (n=151)	0.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 5: Baseline (n=196)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain	Score 5: Month 6 (n=151)	0 percentage of participants

Secondary

Percentage of Participants by Injection Site Pain by ESA Type

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 1: Baseline (n=101)	92.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 2: Baseline (n=101)	6.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 3: Baseline (n=101)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 4: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 5: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 1: Month 6 (n=66)	97.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 2: Month 6 (n=66)	3.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 3: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Mircera: Score 4: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 1: Baseline (n=34)	91.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 2: Baseline (n=34	5.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 3: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 4: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 5: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 1: Month 6 (n=29)	96.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 2: Month 6 (n=29)	3.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 3: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Recormon: Score 4: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 1: Baseline (n=21)	71.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 2: Baseline (n=21)	23.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 3: Baseline (n=21)	4.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 4: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 5: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 1: Month 6 (n=19)	84.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 2: Month 6 (n=19)	15.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 3: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Eprex: Score 4: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 1: Baseline (n=40)	87.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 2: Baseline (n=40)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 3: Baseline (n=40)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 4: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 5: Baseline (n=40)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 1: Month 6 (n=37)	83.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 2: Month 6 (n=37)	8.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 3: Month 6 (n=37)	5.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Injection Site Pain by ESA Type	Aranesp: Score 4: Month 6 (n=37)	2.7 percentage of participants

Secondary

Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 1: Baseline (n=196)	96.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 1: Month 6 (n=151)	97.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 2: Baseline (n=196)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 2: Month 6 (n=151)	0.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 3: Baseline (n=196)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 3: Month 6 (n=151)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 4: Baseline (n=196)	0.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 4: Month 6 (n=151)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 5: Baseline (n=196)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements	Score 5: Month 6 (n=151)	0.7 percentage of participants

Secondary

Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 1: Baseline (n=101)	97.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 2: Baseline (n=101)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 4: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 5: Baseline (n=101)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 1: Month 6 (n=66)	100.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 2: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 3: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Mircera: Score 5: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 1: Baseline (n=34)	100.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 2: Baseline (n=34	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 4: Baseline (n=34	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 5: Baseline (n=34	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 1: Month 6 (n=29)	96.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 2: Month 6 (n=29)	3.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 3: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Recormon: Score 5: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 1: Baseline (n=21)	100.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 2: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 4: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 5: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 1: Month 6 (n=19)	94.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 2: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 3: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Eprex: Score 5: Month 6 (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 1: Baseline (n=40)	90.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 2: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 4: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 5: Baseline (n=40)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 1: Month 6 (n=37)	94.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 2: Month 6 (n=37)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 3: Month 6 (n=37)	5.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types	Aranesp: Score 5: Month 6 (n=37)	0 percentage of participants

Secondary

Percentage of Participants by Need for Improvement in Treatment Frequency

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 1 : Baseline (n=196)	94.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 1 : Month 6 (n=151)	96.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 2 : Baseline (n=196)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 2 : Month 6 (n=151)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 3 : Baseline (n=196)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 3 : Month 6 (n=151)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 4 : Baseline (n=196)	1.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 4 : Month 6 (n=151)	0.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 5 : Baseline (n=196)	0.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency	Score 5 : Month 6 (n=151)	0.7 percentage of participants

Secondary

Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 5: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 3: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 4: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 1: Month 6 (n=37)	89.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 2: Month 6 (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 3: Month 6 (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 4: Month 6 (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 5: Month 6 (n=37)	2.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 1: Baseline (n=101)	98.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 2: Baseline (n=101)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 3: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 4: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 5: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 1: Baseline (n=34)	94.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 2: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 3: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 4: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 5: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 1: Baseline (n=21)	90.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 2: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 3: Baseline (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 4: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 5: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 1: Baseline (n=40)	90.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 2: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 3: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 4: Baseline (n=40)	5.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Aranesp: Score 5: Baseline (n=40)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 1: Month 6 (n=66)	100.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 2: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 3: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 4: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Mircera: Score 5: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 1: Month 6 (n=29)	96.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 2: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 3: Month 6 (n=29)	3.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 4: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Recormon: Score 5: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 1: Month 6 (n=19)	94.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type	Eprex: Score 2: Month 6 (n=19)	5.3 percentage of participants

Secondary

Percentage of Participants by Preferred Treatment Frequency

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Once a month: Baseline (n=196)	63.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Once a month: Month 6 (n=151)	49.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Twice a month: Baseline (n=196)	17.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Twice a month: Month 6 (n=151)	23.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Once a week: Baseline (n=196)	12.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Once a week: Month 6 (n=151)	17.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Twice a week: Baseline (n=196)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Twice a week: Month 6 (n=151)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Three times a week: Baseline (n=196)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Three times a week: Month 6 (n=151)	0.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Other: Baseline (n=196)	3.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency	Other: Month 6 (n=151)	7.3 percentage of participants

Secondary

Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA T/W: Baseline (n=5)	80.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA T/W: Month 6 (n=2)	50.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA B/W: Baseline (n=14)	28.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA B/W: Month 6 (n=6)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA O/W: Baseline (n=29)	27.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA O/W: Month 6 (n=24)	12.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA Q2W: Baseline (n=51)	49.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA Q2W: Month 6 (n=38)	13.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA Q4W: Baseline (n=75)	98.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA Q4W: Month 6 (n=59)	96.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA other: Baseline (n=21)	47.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/M: Baseline ESA other: Month 6 (n=22)	36.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA T/W: Baseline (n=5)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA T/W: Month 6 (n=2)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA B/W: Baseline (n=14)	28.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA B/W: Month 6 (n=6)	33.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA O/W: Baseline (n=29)	10.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA O/W: Month 6 (n=24)	8.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA Q2W: Baseline (n=51)	47.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA Q2W: Month 6 (n=38)	81.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA Q4W: Baseline (n=75)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA Q4W: Month 6 (n=59)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA other: Baseline (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/M: Baseline ESA other: Month 6 (n=22)	4.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA T/W: Baseline (n=5)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA T/W: Month 6 (n=2)	50.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA B/W: Baseline (n=14)	28.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA B/W: Month 6 (n=6)	33.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA O/W: Baseline (n=29)	62.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA O/W: Month 6 (n=24)	79.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA Q2W: Baseline (n=51)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA Q2W: Month 6 (n=38)	2.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA Q4W: Baseline (n=75)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA Q4W: Month 6 (n=59)	1.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA other: Baseline (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred O/W: Baseline ESA other: Month 6 (n=22)	9.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA T/W: Baseline (n=5)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA T/W: Month 6 (n=2)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA B/W: Baseline (n=14)	14.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA B/W: Month 6 (n=6)	33.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA O/W: Baseline (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA O/W: Month 6 (n=24)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA Q2W: Baseline (n=51)	2.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA Q2W: Month 6 (n=38)	2.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA Q4W: Baseline (n=75)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: Baseline ESA Q4W: Month 6 (n=59)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: ESA other: Baseline (n=21)	4.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred B/W: ESA other: Month 6 (n=22)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA T/W: Baseline (n=5)	20.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA T/W: Month 6 (n=2)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA B/W: Baseline (n=14)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA B/W: Month 6 (n=6)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA O/W: Baseline (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA O/W: Month 6 (n=24)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA Q2W: Baseline (n=51)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA Q2W: Month 6 (n=38)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA Q4W: Baseline (n=75)	1.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA Q4W: Month 6 (n=59)	1.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA other: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred T/W: Baseline ESA other: Month 6 (n=22)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA T/W: Baseline (n=5)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA T/W: Month 6 (n=2)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA B/W: Baseline (n=14)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA B/W: Month 6 (n=6)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA O/W: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA O/W: Month 6 (n=24)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA Q2W: Baseline (n=51)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA Q2W: Month 6 (n=38)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA Q4W: Baseline (n=75)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other: Baseline ESA Q4W: Month 6 (n=59)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other:Baseline ESA other:Baseline (n=21)	28.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency	Preferred Other:Baseline ESA other: Month 6 (n=22)	50.0 percentage of participants

Secondary

Percentage of Participants by Preferred Treatment Frequency by ESA Type

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?. Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Once a month: Baseline (n=101)	83.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Once a month: Month 6 (n=66)	75.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Twice a month: Baseline (n=101)	14.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Twice a month: Month 6 (n=66)	15.2 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Once a week: Baseline (n=101)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Once a week: Month 6 (n=66)	3.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Twice a week: Baseline (n=101)	1.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Twice a week: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Three times a week: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Three times a week: Month 6 (n=66)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Other: Baseline (n=101)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Mircera: Other: Month 6 (n=66)	6.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Once a month: Baseline (n=34)	44.1 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Once a month: Month 6 (n=29)	27.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Twice a month: Baseline (n=34)	14.7 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Twice a month: Month 6 (n=29)	31.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Once a week: Baseline (n=34)	35.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Once a week: Month 6 (n=29)	31.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Twice a week: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Twice a week: Month 6 (n=29)	6.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Three times a week: Baseline (n=34)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Three times a week: Month 6 (n=29)	3.4 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Other: Baseline (n=34)	2.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Recormon: Other: Month 6 (n=29)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Once a month: Baseline (n=21)	33.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Once a month: Month 6 (n=19)	10.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Twice a month: Baseline (n=21)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Twice a month: Month 6 (n=19)	15.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Once a week: Baseline (n=21)	42.9 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Once a week: Month 6 (n=19)	52.6 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Twice a week: Baseline (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Twice a week: Month 6 (n=19)	5.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Three times a week: Baseline (n=21)	4.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Three times a week: Month 6 (n=19)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Other: Baseline (n=21)	9.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Eprex: Other: Month 6 (n=19)	15.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Once a month: Baseline (n=40)	47.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Once a month: Month 6 (n=37)	37.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Twice a month: Baseline (n=40)	35.0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Twice a month: Month 6 (n=37)	37.8 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Once a week: Baseline (n=40)	7.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Once a week: Month 6 (n=37)	13.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Twice a week: Baseline (n=40)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Twice a week: Month 6 (n=37)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Three times a week: Baseline (n=40)	2.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Three times a week: Month 6 (n=37)	0 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Other: Baseline (n=40)	7.5 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants by Preferred Treatment Frequency by ESA Type	Aranesp: Other: Month 6 (n=37)	10.8 percentage of participants

Secondary

Percentage of Participants With Interest in Learning to Inject Independently

Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.

Time frame: Baseline, Month 6

Population: All enrolled participants who did not inject independently. Here 'n' signifies number of participants evaluable at specified time-points.

Arm	Measure	Group	Value (NUMBER)
Chronic Renal Anemia Participants	Percentage of Participants With Interest in Learning to Inject Independently	Baseline (n=160)	6.3 percentage of participants
Chronic Renal Anemia Participants	Percentage of Participants With Interest in Learning to Inject Independently	Month 6 (n=116)	4.3 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants by ESA Types at Baseline

Percentage of Participants by ESA Types at Month 6

Percentage of Participants by Frequency and Types of ESA Used at Baseline

Percentage of Participants by Frequency and Types of ESA Used at Month 6

Percentage of Participants by Frequency of ESA Use at Baseline

Percentage of Participants by Frequency of ESA Use at Month 6

Percentage of Participants by Convenience of Syringe Usage

Percentage of Participants by Convenience of Syringe Usage by ESA Type

Percentage of Participants by Different CKD Stages

Percentage of Participants by Different Injection Administration Modes

Percentage of Participants by Injection Site Pain

Percentage of Participants by Injection Site Pain by ESA Type

Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements

Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types

Percentage of Participants by Need for Improvement in Treatment Frequency

Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type

Percentage of Participants by Preferred Treatment Frequency

Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency

Percentage of Participants by Preferred Treatment Frequency by ESA Type

Percentage of Participants With Interest in Learning to Inject Independently